MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK) (“MiddleBrook” or the “Company”) has filed a voluntary petition (the “Petition”) for relief under Chapter 11 of the United...
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced that James H. Cavanaugh, Ph.D., Martin A. Vogelbaum and Harold R. Werner have resigned from the Company’s Board...
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced that it has entered into an agreement with DoctorDirectory.com Inc., the Company’s promotion partner for MOXATAG...
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced its 2009 fourth quarter and full-year results, that it is further restructuring to reduce expenses, and that it...
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) announced today that it is partnering with DoctorDirectory.com, Inc. (DoctorDirectory) to promote MOXATAG through...
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) announced today that on Dec. 31, 2009, it granted options to purchase a total of 5,000 shares of MiddleBrook's common stock to...
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced a reduction of its field sales force and corporate staff. Effective December 4, 2009, MiddleBrook will reduce...
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced its financial and operational results for the quarter ended Sept. 30, 2009. “MOXATAG tripled its share of the...
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is scheduled to announce its results for the 2009 third quarter on Thursday, Nov. 5, 2009, before the market opens. At 9:00 a.m...
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), the maker of the first and only FDA-approved once-daily amoxicillin, MOXATAG (extended-release amoxicillin) Tablets, 775 mg...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約